Theranica’s Nerivio Wearable Device Receives CE Mark for Acute Treatment of Migraine in Europe

Shots:

• The CE mark is granted under the new MDR European regulation, allowing the wearable therapeutic device to be marketed in selected EU countries, starting in 2021
• Nerivio has also received the US FDA’s approval for use in the acute treatment of migraine and is currently under review for chronic migraine. Nerivio is the first smartphone-controlled wearable device, connected with an app that keeps tracks of migraine episodes and provides analytics that a patient can share with their doctor, to help monitor and tailor treatment
• Nerivio is a wireless remote electrical neuromodulation device for the acute treatment of migraine with/out aura in patients ≥18yrs. who do not have chronic migraine. The device is self-applied to the upper-arm and should be used in the home environment at the onset of migraine headache or aura

Click here ­to­ read full press release/ article | Ref: Theranica | Image: Theranica